Marshall Wace’s VanEck Pharmaceutical ETF PPH Stock Holding History

Marshall Wace’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$809K	Sell	7,398 -9,646	-57%	-$998K	﹤0.01%	2305
2026 Q1	$1.77M	Sell	17,044 -9,426	-36%	-$1M	﹤0.01%	1855
2025 Q4	$2.73M	Buy	26,470 +17,256	+187%	+$1.68M	﹤0.01%	1423
2025 Q3	$833K	Buy	+9,214	New	+$807K	﹤0.01%	2019
2025 Q1	–	Sell	-14,232	Closed	-$1.23M	–	2996
2024 Q4	$1.23M	Buy	14,232 +11,111	+356%	+$1.01M	﹤0.01%	1639
2024 Q3	$297K	Sell	3,121 -2,251	-42%	-$214K	﹤0.01%	2149
2024 Q2	$491K	Buy	+5,372	New	+$480K	﹤0.01%	1965
2023 Q4	–	Sell	-7,776	Closed	-$621K	–	2520
2023 Q3	$621K	Buy	+7,776	New	+$627K	﹤0.01%	1654
2023 Q1	–	Sell	-13,155	Closed	-$1.02M	–	3010
2022 Q4	$1.02M	Buy	13,155 +557	+4%	+$41.1K	﹤0.01%	2081
2022 Q3	$848K	Buy	12,598 +7,330	+139%	+$540K	﹤0.01%	2478
2022 Q2	$404K	Buy	5,268 +628	+14%	+$49K	﹤0.01%	2894
2022 Q1	$370K	Buy	+4,640	New	+$355K	﹤0.01%	2908

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Marshall Wace's PPH Position: Q2 2026 in Review

Marshall Wace reduced its VanEck Pharmaceutical ETF (PPH) stake by 57% in Q2 2026, selling an estimated $998K and leaving 7,398 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Marshall Wace first reported a position in PPH in Q1 2022 and has held it in 12 quarters since. The position peaked at $2.73M in Q4 2025. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Marshall Wace held 7,398 shares of VanEck Pharmaceutical ETF worth $809K as of Q2 2026.
Marshall Wace sold 9,646 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $998K.
VanEck Pharmaceutical ETF made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2305 holding.
Marshall Wace first reported a position in VanEck Pharmaceutical ETF in Q1 2022 and has held it in 12 quarters since.
Marshall Wace's VanEck Pharmaceutical ETF position peaked at $2.73M in Q4 2025.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.